For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Korea Signs Agreement with Daewoong Pharmaceutical for the Co-promotion of LIXIANA® in South Korea

Tokyo, Japan (December 28, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. (hereafter “DSKR;” headquarters: Jongno-gu, Seoul, South Korea), and Daewoong Pharmaceutical Co., Ltd. (hereafter “Daewoong Pharmaceutical;” headquarter: Gangnam-gu, Seoul, South Korea) have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA^® (generic name: edoxaban).

 

Daewoong Pharmaceutical is also the co-promotion partner in South Korea for the Daiichi Sankyo antihypertensives Olmetec^®, Olmetec Plus^®, Sevikar^®, Sevikar HCT^®, and through this new agreement, Daiichi Sankyo Korea aims to maximize LIXIANA’s product value and further contribute to disease treatment and prevention in South Korea.

 

LIXIANA was approved in South Korea in August 2015 and will be launched within this fiscal year.